Ann C Childress
Overview
Explore the profile of Ann C Childress including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
683
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baweja R, Faraone S, Childress A, Weiss M, Loo S, Wilens T, et al.
J Child Adolesc Psychopharmacol
. 2024 Apr;
34(4):167-182.
PMID: 38686563
This review aims to present recent innovations and advancements in attention-deficit/hyperactivity disorder (ADHD) care, encompassing international consensus statement, new medication formulations, digital therapeutics, and neurostimulation devices. A comprehensive literature search...
2.
Arnold V, Lopez F, Childress A, Po M, Uchida C, Cuthbertson L, et al.
J Atten Disord
. 2024 Apr;
28(8):1186-1197.
PMID: 38600754
Objective: DR/ER-MPH (formerly HLD200) is an evening-dosed delayed-release and extended-release methylphenidate approved for the treatment of ADHD in patients ≥6 years. analyses of two pivotal Phase 3 trials: HLD200-107 (NCT02493777)...
3.
Cutler A, Kollins S, Brams M, Corliss M, Oh C, Braeckman R, et al.
Front Psychiatry
. 2024 Apr;
15:1310483.
PMID: 38566957
Objective: To evaluate treatment responder rate using the Attention-Deficit/Hyperactivity Disorder Rating Scale-5 (ADHD-RS-5) score based on optimized dose level of serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) and changes in ADHD severity in children (aged...
4.
Mattingly G, Childress A, Cutler A, Estrada J, Corliss M
Front Psychiatry
. 2023 Jul;
14:1193455.
PMID: 37426086
Introduction: Sleep-related problems are common in children with attention-deficit/hyperactivity disorder (ADHD). Sleep disorders are also side effects of all stimulant ADHD medications. Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a once-daily treatment approved for...
5.
Childress A, Cutler A, Patel M, Oh C
J Child Adolesc Psychopharmacol
. 2023 May;
33(4):134-142.
PMID: 37204277
Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A 12-month, open-label safety study with SDX/d-MPH in children with ADHD showed that SDX/d-MPH...
6.
Childress A, Marraffino A, Cutler A, Oh C, Brams M
J Child Adolesc Psychopharmacol
. 2023 Feb;
33(2):51-58.
PMID: 36809150
Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A pivotal double-blind (DB) study of children aged 6-12 years with ADHD demonstrated efficacy...
7.
Faraone S, Childress A, Gomeni R, Rafla E, Kando J, Dansie L, et al.
J Child Adolesc Psychopharmacol
. 2023 Feb;
33(1):14-19.
PMID: 36730749
To evaluate the treatment effect size throughout the day of amphetamine extended-release oral suspension (AMPH EROS; Tris Pharma, Inc., Monmouth Junction, NJ, USA) in a laboratory classroom study conducted in...
8.
Childress A, Yu K, Cuthbertson L
CNS Drugs
. 2022 Dec;
37(1):31-44.
PMID: 36520318
Attention-deficit/hyperactivity disorder (ADHD) is a common and impairing mental disorder. Individuals with ADHD typically experience symptoms from awakening throughout the entire day, contributing to impaired function at home, at school,...
9.
Cutler A, Childress A, Pardo A, Duhoux S, Gomeni R, Rafla E, et al.
J Clin Psychiatry
. 2022 Jul;
83(5).
PMID: 35857716
To evaluate the efficacy and safety of amphetamine extended-release tablets (AMPH ER TAB) in adults with attention-deficit/hyperactivity disorder (ADHD). In a 5-week forced-dose titration phase, subjects were randomized to either...
10.
Childress A
Child Adolesc Psychiatr Clin N Am
. 2022 Jun;
31(3):373-392.
PMID: 35697391
Stimulants have been available for the treatment of attention-deficit/hyperactivity disorder (ADHD) for more than 70 years and are the most effective medications available. During the past 2 decades, several new...